Telaprevir for HIV/Hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 telapreVIH): An open-label, single-arm, phase 2 trial

Clinical Infectious Diseases

Volumn 59, Issue 12, 2014, Pages 1768-1776

  Cotte, Laurent ^a   Braun, Joséphine ^b   Lascoux Combe, Caroline ^c   Vincent, Corine ^b   Valantin, Marc Antoine ^d   Sogni, Philippe ^e   Lacombe, Karine ^f   Neau, Didier ^g   Aumaitre, Hugues ^h   Batisse, Dominique ⁱ   De Truchis, Pierre ^j   Gervais, Anne ^k   Michelet, Christian ^l   Morlat, Philippe ^m   Vittecoq, Daniel ⁿ   Rosa, Isabelle ^o   Bertucci, Inga ^p   Chevaliez, Stéphane ^q   Aboulker, Jean Pierre ^b   Molina, Jean Michel ^c  

^a CROIX ROUSSE HOSPITAL   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g HÔPITAL PELLEGRIN   (France)

^h Saint Jean Hospital   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j RAYMOND POINCARÉ HOSPITAL   (France)

^k BICHAT HOSPITAL   (France)

^l Pontchaillou University Hospital Rennes   (United States)

^m HÔPITAL SAINT ANDRÉ   (France)

ⁿ BICÊTRE HOSPITAL   (France)

^o Créteil Hospital   (France)

^p French National Agency for Research on AIDS and Viral Hepatitis   (France)

^q HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

direct acting agent; HCV retreatment; HIV HCV coinfection; telaprevir

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CORTICOSTEROID; EFAVIRENZ; EMTRICITABINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RALTEGRAVIR; SERUM ALBUMIN; TELAPREVIR; TENOFOVIR; THROMBOPOIETIN RECEPTOR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; AUTOIMMUNE THROMBOCYTOPENIA; BRAIN HEMORRHAGE; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN DETERMINATION; HEMORRHOID; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; CLINICAL TRIAL; COINFECTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84918529048     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu659     Document Type: Article

References (39)

1. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008; 47: 94-101.
2. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
3. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-8.
4. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-48.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
8. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
9. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
10. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-36.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-50.
12. Crespo M, Mira JA, Pineda JA, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother 2008; 62:793-6.
13. Labarga P, Vispo E, Barreiro P, et al. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr 2010; 53:364-8.
14. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virusco-infected non-responders and relapsers to IFN-based therapy. AIDS 2004; 18:75-9.
15. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007; 38:32-8.
16. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype-1 infection. N Engl J Med 2011; 364:1207-17.
17. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
18. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype-1 infection. N Engl J Med 2011; 364:1195-206.
19. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
20. Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther 2012; 34:1857-82.
21. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
22. Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19:1-26.
23. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther 2013; 35:190-7.
24. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype-1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
25. Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther 2012; 17:1211-21.
26. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther 2013; 18:553-60.
27. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype-1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-8.
28. Chevaliez S, Hezode C, Soulier A, et al. High-dose pegylated interferonalpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology 2011; 141:119-27.
29. French National Agency for Research on AIDS and Viral Hepatitis. ANRS scale to grade the severity of adverse events in adults. Version 1.0. Available at: http://www.anrs.fr/content/download/2242/12805/ file/ANRS-GradeEI-V1-En-2008.pdf. Accessed 29 August 2014.
30. Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype-1 coinfected patients: a randomized international trial. HIV Clin Trials 2012; 13:142-52.
31. Martel-Laferriere V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15:108-15.
32. Pol S, Aerssens J, Zeuzem S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol 2013; 58:883-9.
33. Incivo. Summary of product characteristics. London: European Medicines Agency, 10 March 2011 [updated 12 April 2013]. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf. Accessed 29 August 2014.
34. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996; 25:972-5.
35. Elefsiniotis IS, Pantazis KD, Fotos NV, Moulakakis A, Mavrogiannis C. Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C. J Gastroenterol Hepatol 2006; 21:622-3.
36. Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008; 112:542-50.
37. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)- NCT01514890. J Hepatol 2013; 59:434-41.
38. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C, 2014. Available at: http://files.easl. eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf. Accessed 29 August 2014.
39. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med 2014; 370:1552-3.